Journal of Microbiology

Journal Article

Comprehensive Analysis of Gut Microbiota Alteration in the Patients and Animal Models with Polycystic Ovary Syndrome: Jing Zhou , Xuemei Qiu , Xuejing Chen , Sihan Ma , Zhaoyang Chen , Ruzhe Wang , Ying Tian , Yufan Jiang , Li Fan , Jingjie Wang; J. Microbiol. 2023;61(9):821-836. Published online October 12, 2023; DOI: https://doi.org/10.1007/s12275-023-00079-9

60 View
0 Download
3 Web of Science
3 Crossref

Polycystic ovary syndrome (PCOS) is a common disease of endocrine–metabolic disorder, and its etiology remains largely unknown. The gut microbiota is possibly involved in PCOS, while the association remains unclear. The comprehensive analysis combining gut microbiota with PCOS typical symptoms was performed to analyze the role of gut microbiota in PCOS in this study. The clinical patients and letrozole-induced animal models were determined on PCOS indexes and gut microbiota, and fecal microbiota transplantation (FMT) was conducted. Results indicated that the animal models displayed typical PCOS symptoms, including disordered estrous cycles, elevated testosterone levels, and ovarian morphological change; meanwhile, the symptoms were improved after FMT. Furthermore, the microbial diversity exhibited disordered, and the abundance of the genus Ruminococcus and Lactobacillus showed a consistent trend in PCOS rats and patients. The microbiota diversity and several key genera were restored subjected to FMT, and correlation analysis also supported relevant conclusions. Moreover, LEfSe analysis showed that Gemmiger, Flexispira, and Eubacterium were overrepresented in PCOS groups. Overall, the results indicate the involvement of gut microbiota in PCOS and its possible alleviation of endocrinal and reproductive dysfunctions through several special bacteria taxa, which can function as the biomarker or potential target for diagnosis and treatment. These results can provide the new insights for treatment and prevention strategies of PCOS.

Citations

Citations to this article as recorded by

Gut Microbes in Polycystic Ovary Syndrome and Associated Comorbidities; Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease (NAFLD), Cardiovascular Disease (CVD), and the Potential of Microbial Therapeutics
Vineet Singh, Kanika Mahra, DaRyung Jung, Jae-Ho Shin
Probiotics and Antimicrobial Proteins.2024; 16(5): 1744. CrossRef
Potential therapeutic application and mechanism of gut microbiota-derived extracellular vesicles in polycystic ovary syndrome
Liangliang Yang, Tingxiu Liu, Yan Liao, Yuehan Ren, Zheng Zheng, Mingyue Zhang, Yue Yu, Chang Liu, Chaoying Wang, Tong Chen, Lili Zhang, Dongxue Zheng, Haidan Zhao, Zhexin Ni, Xinmin Liu
Biomedicine & Pharmacotherapy.2024; 180: 117504. CrossRef
Research Advance on the Prevention and Treatment of Polycystic Ovary Syndrome Based on Dysbiosis of Gut Microbiota
钰炜王
Advances in Clinical Medicine.2024; 14(08): 895. CrossRef

Research Support, Non-U.S. Gov't

Antimicrobial Effect of Korean Propolis Against the Mutans Streptococci Isolated from Korean: Min Jung Kim , Chun Sung Kim , Byung-Hoon Kim , Sang-Bok Ro , Yun Kyong Lim , Soon-Nang Park , Engene Cho , Jang-Hyuk Ko , Soon-Sung Kwon , Yeong-Mu Ko , Joong-Ki Kook; J. Microbiol. 2011;49(1):161-164. Published online March 3, 2011; DOI: https://doi.org/10.1007/s12275-011-1002-8

29 View
0 Download
24 Scopus

Abstract: The aim of this study was to determine the optimal concentration of Korean propolis against clinical isolates of mutans streptococci (MS) from Koreans. The antimicrobial activity was evaluated using the minimum inhibitory concentration (MIC) and time-kill curves against mutans streptococci. The MIC90 values of propolis for MS were 35 μg/ml. Propolis had a bacteriostatic effect on Streptococcus mutans ATCC 25175T and bactericidal effects on Streptococcus sobrinus ATCC 33478T at > 2×MIC (70 μg/ml). These results suggest that the propolis can be used in the development of oral hygiene products for the prevention of dental caries.

First
Prev
Page of 1
Next
Last

Search